The program investigates a nanoparticle API used as an adjuvant to enhance the efficacy of oxaliplatin.
Mesothelioma is a type of cancer that develops in the lining that covers the outer surface of some of the body's organs. Oxaliplatin is given in IV form and has long term use in colon cancers. Adverse effects are well documented and extensive (more than 30% reported) with common side effects including pain, low blood counts, fatigue, and loss of appetite.
Objective response rates of greater than or equal to 50% have been reported for first-line therapy, decreasing to 13% - 45% for second-line therapy. Sensory neuropathy is the main cumulative dose-limiting factor in patients receiving oxaliplatin.
Regardless, generally speaking, about <30% of patients achieve an objective response rate, median overall survival is typically only around 12 months.
In vitro work is demonstrating that the use of NanoCelle® (Medlab's proprietary delivery platform) along with specific short chain fatty acids demonstrated enhanced adjuvant destruction of mesothelioma cells.
This program is to further the initial research endeavours in the hope of proving a more efficacious medication.